Daniela Vilasboas-Campos

Ms. Daniela Vilasboas-Campos

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
DVDaniela Vilasboas-Campos
Daniela Vilasboas-Campos
MCMarta Costa
Marta Costa
ATAndreia Teixeira-Castro
Andreia Teixeira-Castro
RRRejaine Rios
Rejaine Rios
FSFabiano Guimarães Silva
Fabiano Guimarães Silva
Patrícia MacielPatrícia Maciel
Patrícia Maciel

5 August 2023 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
FFFrancisco Figueiredo
Francisco Figueiredo
ZSZsuzsa Sárkány
Zsuzsa Sárkány
ASAlexandra Silva
Alexandra Silva
DVDaniela Vilasboas-Campos
Daniela Vilasboas-Campos
Patrícia MacielPatrícia Maciel
Patrícia Maciel
SMSandra Macedo-Ribeiro
Sandra Macedo-Ribeiro
The accumulation of mutant ataxin-3 (Atx3) in neuronal nuclear inclusions is a pathological hallmark of Machado-Joseph disease (MJD), also known as Spinocerebellar Ataxia Type 3. Decreasing the protein aggregation burden is a possible disease-modifying strategy to tackle MJD and other neurodegenerative disorders for which only symptomatic treatments are currently available. We performed a drug repurposing screening to identify inhibitors of Atx3 aggregation with known toxicological and pharmacokinetic profiles. Interestingly, dopamine hydrochloride and other catecholamines are among the most potent inhibitors of Atx3 aggregation in vitro. Our results indicate that low micromolar concentrations of dopamine markedly delay the formation of mature amyloid fibrils of mutant Atx3 through the inhibition of the earlier oligomerization steps. Although dopamine itself does not cross the blood-brain barrier, dopamine levels in the brain can be increased by low doses of dopamine precursors and dopamine agonists commonly used to treat Parkinsonian symptoms. In agreement, treatment with levodopa ameliorated motor symptoms in a C. elegans model of MJD. These findings suggest a possible application of dopaminergic drugs to halt or reduce Atx3 accumulation in the brains of MJD patients.

3 February 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
AJAna Jalles
Ana Jalles
CVCármen Vieira
Cármen Vieira
Joana Pereira-SousaJoana Pereira-Sousa
Joana Pereira-Sousa
DVDaniela Vilasboas-Campos
Daniela Vilasboas-Campos
AMAna Francisca Mota
Ana Francisca Mota
Andreia Teixeira-CastroAndreia Teixeira-Castro
Andreia Teixeira-Castro
The atypical antipsychotic aripiprazole is a Food and Drug Administration-approved drug for the treatment of psychotic, mood, and other psychiatric disorders. Previous drug discovery efforts pinpointed aripiprazole as an effective suppressor of Machado–Joseph disease (MJD) pathogenesis, as its administration resulted in a reduced abundance and aggregation of mutant Ataxin-3 (ATXN3) proteins. Dopamine partial agonism and functional selectivity have been proposed as the main pharmacological mechanism of action of aripiprazole in the treatment of psychosis; however, this mechanism remains to be determined in the context of MJD. Here, we focus on confirming the efficacy of aripiprazole to reduce motor dysfunction in vivo, using a Caenorhabditis elegans (C. elegans) model of MJD, and on unveiling the drug targets required for its positive action against mutant ATXN3 pathogenesis. We employed pharmacogenetics and pharmacological approaches to identify which dopamine and serotonin receptors are critical for aripiprazole-mediated improvements in motor function. We demonstrated that dopamine D2-like and serotonin 5-HT1A and 5-HT2A receptors play important roles in this process. Our findings strengthen the relevance of dopaminergic and serotoninergic signaling modulation against mutant ATXN3-mediated pathogenesis. The identification of aripiprazole’s cellular targets, relevant for MJD and perhaps other neurodegenerative diseases, may pave the way for prospective drug discovery and development campaigns aiming to improve the features of this prototypical compound and reduce side effects not negligible in the case of aripiprazole.

Verified
Journal Article
Open access
PDF file
Jorge H FernandesJorge H Fernandes
Jorge H Fernandes
MCMarta Costa
Marta Costa
DVDaniela Vilasboas-Campos
Daniela Vilasboas-Campos
BFBruna Ferreira-Lomba
Bruna Ferreira-Lomba
Joana Pereira-SousaJoana Pereira-Sousa
Joana Pereira-Sousa
Patrícia MacielPatrícia Maciel
Patrícia Maciel
Hemerocallis citrina is an herbaceous perennial plant used in Asian cuisine and Traditional Chinese Medicine. Here, we tested the therapeutic potential of extracts (HCE30%, HCE50%, and HCN) in vivo, using models of two human genetic neurodegenerative diseases—Machado–Joseph Disease/Spinocerebellar Ataxia type 3 (MJD/SCA3) and Frontotemporal Dementia with Parkinsonism associated to chromosome 17 (FTDP-17). Chronic treatment with HCE30% extract ameliorated the motor deficits typically observed in these models. Interestingly, we found that the effect on the motor phenotype of the MJD/SCA3 model was dependent on serotonergic signaling and on the action of the HLH-30/TFEB transcription factor, known to regulate the cellular response to amino acid starvation, the autophagy and mitophagy pathways, lysosome localization and biogenesis, exocytosis, and mitochondrial biogenesis. Altogether, our findings reinforce the idea that phytochemicals act through the modulation of serotonergic neurotransmission and introduce a novel layer to the HLH-30/TFEB regulatory network. Thus, it also strengthens the use of these pathways as therapeutic targets for protein-related neurodegenerative disorders and confirms the utility of medicinal plants as a source of innovation in the quest for new therapeutic agents.

26 August 2025 in bioRxiv
Verified
Preprint
Open access
BFBruna Ferreira-Lomba
Bruna Ferreira-Lomba
Sara GuerreiroSara Guerreiro
Sara Guerreiro
SDSara Duarte-Silva
Sara Duarte-Silva
DCD Cunha-Garcia
D Cunha-Garcia
SOS Oliveira
S Oliveira
Patrícia MacielPatrícia Maciel
Patrícia Maciel
Background: Spinocerebellar ataxia type 3 (SCA3) is an autosomal dominant neurodegenerative disorder caused by an elongated polyglutamine (polyQ) sequence in the ataxin-3 protein. This expansion triggers neuropathological events, leading to progressive motor disturbances. Currently, no approved therapy exists for this debilitating condition, but compelling evidence suggests that targeting the serotonergic system can significantly attenuate SCA3 disease progression in animal models. Objective: This study aimed to assess the effects of NLX-112, a highly selective serotonin 1A receptor (5-HT 1A R) full agonist, in the CMVMJD135 transgenic mouse model of SCA3. Methods: NLX-112 (0.625 and 5 mg/kg/day) and tandospirone (a 5-HT 1A R partial agonist used as a comparator; 20 and 80 mg/kg/day) were administered chronically in drinking water for 34 weeks, starting prior to symptom onset. To evaluate the effects of the drugs on SCA3 mice, motor-related behavioral tests and neuropathological techniques were employed. Results: Treatment with the higher dose of NLX-112 led to improvements in motor coordination and balance, and slowing of symptom deterioration as the disease progressed. These beneficial effects were not achieved with tandospirone. NLX-112 treatment also elicited neuroprotective effects, reducing dopaminergic (tyrosine hydroxylase-positive) cell loss and astrocyte reactivity in the substantia nigra. Conclusions: NLX-112 treatment, started pre-symptomatically, enhanced motor function, slowed disease progression and elicited neuroprotective effects in SCA3 mice, supporting its further development as a drug candidate for treatment of ataxia and related movement disorders. Graphical Key findings: NLX-112 attenuated motor deficits of SCA3 mice, when administered chronically prior to disease onset. NLX-112 reduced neuropathological biomarkers in SCA3 mice, namely by restoring dopaminergic neuron loss and decreasing astrocyte reactivity. NLX-112 is a potential candidate for addressing ataxia-related deficits in SCA3 patients.

30 January 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Jorge H FernandesJorge H Fernandes
Jorge H Fernandes
MCMarta Costa
Marta Costa
DVDaniela Vilasboas-Campos
Daniela Vilasboas-Campos
Joana Pereira-SousaJoana Pereira-Sousa
Joana Pereira-Sousa
BFBruna Ferreira-Lomba
Bruna Ferreira-Lomba
Patrícia MacielPatrícia Maciel
Patrícia Maciel
Hemerocallis citrina is an herbaceous perennial plant used in Asian cuisine and in Traditional Chinese Medicine. Here, we tested the therapeutic potential for a extracts (HCE30%, HCE50% and HCN) in vivo, using models of two human genetic neurodegenerative diseases – Machado-Joseph Disease/Spinocerebellar Ataxia type 3 and Frontotemporal Dementia with Parkinsonism associated to chromosome 17. Chronic treatment with HCE30% extract ameliorated the motor deficits typically observed in these models. Interestingly, we found that the effect on the motor phenotype of the MJD/SCA3 model was dependent on serotonergic signalling and on the action of the HLH-30/TFEB transcription factor, known to regulate the cellular response to amino acid starvation, the autophagy and mitophagy pathways, lysosome localization and biogenesis, exocytosis and mitochondrial biogenesis. Altogether, our findings reinforce the idea that phytochemicals act through the modulation of serotonergic neurotransmission and introduce a novel layer to the HLH-30/TFEB regulatory network. Thus, also strengthen the use of these pathways as therapeutic targets for protein-related neurodegenerative disorders and confirm the utility of medicinal plants as a source of innovation, in the quest for new therapeutic agents.